BioSpace News Archive

Nicox SA, an international ophthalmology company, provided financial and business highlights for the first quarter 2023 for Nicox SA and its subsidiaries.

Lytix Biopharma AS, a clinical stage immuno-oncology company, announces the election of a new Chairman of the Board at ‘s General Assembly.

Immuron Limited is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar.

Bright Minds Biosciences Inc. announced that the International Searching Authority reviewed its international patent application directed to phenethylamine compounds and issued a Written Opinion indicating that Bright Minds’ core phenethylamine compounds of interest are novel and inventive over the searched prior art.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the presentation of two posters with research results on TNX-1700 (recombinant TFF2 – albumin fusion peptide) at the American Association for Cancer Research (AACR) Annual Meeting, held April 14-19, 2023, in Orlando, Fla.

MacuHealth, the leader in innovative eye supplements, is introducing LifeMeter, a portable, non-invasive device proven to measure the presence of vital antioxidants known as carotenoids.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced two presentations were given at the 33rd Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Copenhagen.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2023 after the market closes on Wednesday, April 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 AM ET.

Inversago Pharma Inc. today announced that François Ravenelle, Ph.D., Chief Executive Officer, will present at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 11:00 a.m. ET.